Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

523 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. Zelenetz AD, et al. Among authors: vose jm. J Natl Compr Canc Netw. 2010 Mar;8(3):288-334. doi: 10.6004/jnccn.2010.0021. J Natl Compr Canc Netw. 2010. PMID: 20202462 No abstract available.
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Cheson BD, et al. Among authors: vose j. J Clin Oncol. 1999 Apr;17(4):1244. doi: 10.1200/JCO.1999.17.4.1244. J Clin Oncol. 1999. PMID: 10561185 Review.
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, Capizzi RL. Bennett JM, et al. Among authors: vose jm. Blood. 2005 Jun 15;105(12):4576-82. doi: 10.1182/blood-2004-12-4690. Epub 2005 Feb 24. Blood. 2005. PMID: 15731177 Free article.
Senior adult oncology clinical practice guidelines in oncology.
Balducci L, Cohen HJ, Engstrom PF, Ettinger DS, Halter J, Gordon LI, Kiel K, Kneier A, Lim D, Petersdorf SH, Rosenthal R, Silliman R, Vose JM, Walker MJ, Zachariah B; National Comprehensive Cancer Network. Balducci L, et al. Among authors: vose jm. J Natl Compr Canc Netw. 2005 Jul;3(4):572-90. doi: 10.6004/jnccn.2005.0032. J Natl Compr Canc Netw. 2005. PMID: 16038647 No abstract available.
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M. Fisher RI, et al. Among authors: vose jm. J Clin Oncol. 2005 Oct 20;23(30):7565-73. doi: 10.1200/JCO.2004.00.9217. Epub 2005 Sep 26. J Clin Oncol. 2005. PMID: 16186600 Clinical Trial.
523 results